atopaxar (E5555) / Eisai - LARVOL DELTA

Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. (PubMed) - "Vorapaxar and atopaxar are novel antiplatelet drugs that inhibit the thrombin-induced platelet activation by antagonizing the PAR-1. The objective of this article is to review the mechanism of action of vorapaxar and atopaxar and explain the rationale for using them in atherothrombosis patients including myocardial infarction, peripheral arterial disease, and stroke."

Journal • Acute Coronary Syndrome • Atherosclerosis • Biosimilar • Dyslipidemia • Immunology • Inflammation

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease (clinicaltrials.gov) - P2; N=720; Completed; Sponsor: Eisai Inc.; N=600 ➔ 720

Enrollment change • Acute Coronary Syndrome • Biosimilar • Immunology • Reperfusion Injury